Composition for treating cancer associated with hpv infection

Abstract

The present invention relates to a composition for preventing or treating diseases associated with human papillomavirus (HPV), and more specifically, cancer associated with HPV, and even more specifically, cervical cancer. The nucleotide sequence of the present invention, the sequence in which the base thereof is modified, and a specific combination thereof can be useful in a composition for effectively treating diseases associated with HPV infection by greatly inhibiting the expression of the E6/E7 gene of HPV type 16 or 18.

1 . A composition for treating or preventing a disease caused by human papilloma virus (HPV) infection, the composition comprising, as an active ingredient, one or more nucleotide sequences selected from the group consisting of sequences of nucleotide comprising SEQ ID NOs: 16, 22, 28, 34, 40, 66, 72, 84, 90, and 108, and antisense nucleotide sequences thereof. 
     
     
         2 . A composition for treating or preventing a disease caused by HPV infection, the composition comprising, as an active ingredient, one or more nucleotide sequences selected from the group consisting of sequences of nucleotide comprising SEQ ID NOs: 1, 7, 12, 16, 22, 28, 34, 40, 46, 51, 56, 62, 66, 72, 78, 84, 90, 96, 102 and 108, and antisense nucleotide sequences thereof which include a modified backbone or one or more modified bases. 
     
     
         3 . The composition of  claim 2 , wherein, the modified backbone comprises one or more modifications selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonotioate, phosphoamidate, phosphate ester, carbamate, acetamidate, carboxymethyl ester, carbonate, and phosphate triester. 
     
     
         4 . The composition of  claim 2 , wherein, the modified base comprises one or more modifications selected from the group consisting of methylation, glycosylation and halogenation. 
     
     
         5 . The composition of  claim 4 , wherein, the modified base is a 2′-O methylated or a 2′-fluorinated base. 
     
     
         6 . The composition of  claim 5 , wherein, the 2′-0 methylated base is U or G. 
     
     
         7 . The composition of  claim 5 , wherein, the 2′-fluorinated base is C. 
     
     
         8 . The composition of  claim 5 , wherein, the nucleotide sequence comprising the 2′-O methylated or the 2′-fluorinated base is selected from the group consisting of sequences of nucleotide comprising SEQ ID NOs: 2, 3, 5, 6, 8, 10, 11, 13, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 41, 42, 44, 45, 47, 49, 50, 52, 54, 55, 57, 58, 60, 61, 63, 65, 67, 68, 70, 71, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95, 97, 98, 100, 101, 103, 104, 106, 107, 109, 110, 112 and 113. 
     
     
         9 . The composition of  claim 1 , wherein, the nucleotide is small interfering RNA (siRNA), short hairpin RNA (shRNA), or an antisense oligonucleotide (ASO). 
     
     
         10 . The composition of  claim 9 , wherein, the nucleotide is siRNA. 
     
     
         11 . A composition for preventing or treating a disease caused by HPV infection, the composition comprising, as an active ingredient, a nucleotide pool selected from the group consisting of: a pool having nucleotide sequences of SEQ ID Nos: 2, 4, 8, 9, 12, and 15; a pool having nucleotide sequences of SEQ ID Nos: 18, 21, 29, and 32; a pool having nucleotide sequences of SEQ ID Nos: 42, 45, 52, and 55; a pool having nucleotide sequences of SEQ ID Nos: 58, 59, 63 and 65; a pool having nucleotide sequences of SEQ ID Nos: 68, 71, 91 and 94; and a pool having nucleotide sequences of SEQ ID Nos: 98, 100, 109 and 112. 
     
     
         12 . The composition of  claim 1 , wherein, the disease associated with HPV infection is selected from the group consisting of genital warts, vagina inflammation, pelvic inflammation and a cancer. 
     
     
         13 . The composition of  claim 12 , wherein, the cancer is selected from the group consisting of cervical cancer, vagina cancer, vulva cancer, anal cancer, penis cancer, tonsil cancer, pharynx cancer, larynx cancer, head and neck cancer and lung adenocarcinoma. 
     
     
         14 - 26 . (canceled) 
     
     
         27 . The composition of  claim 2 , wherein, the nucleotide is small interfering RNA (siRNA), short hairpin RNA (shRNA), or an antisense oligonucleotide (ASO). 
     
     
         28 . The composition of  claim 27 , wherein, the nucleotide is siRNA 
     
     
         29 . The composition of  claim 2 , wherein, the disease associated with HPV infection is selected from the group consisting of genital warts, vagina inflammation, pelvic inflammation and a cancer. 
     
     
         30 . The composition of  claim 29 , wherein, the cancer is selected from the group consisting of cervical cancer, vagina cancer, vulva cancer, anal cancer, penis cancer, tonsil cancer, pharynx cancer, larynx cancer, head and neck cancer and lung adenocarcinoma. 
     
     
         31 . The composition of  claim 11 , wherein, the disease associated with HPV infection is selected from the group consisting of genital warts, vagina inflammation, pelvic inflammation and a cancer. 
     
     
         32 . The composition of  claim 31 , wherein, the cancer is selected from the group consisting of cervical cancer, vagina cancer, vulva cancer, anal cancer, penis cancer, tonsil cancer, pharynx cancer, larynx cancer, head and neck cancer and lung adenocarcinoma.